Can a Controlled-Release Oral Dose Form of Oxycodone Be Used as Readily as an Immediate-Release Form for the Purpose of Titrating to Stable Pain Control?

• Published in: Journal of pain and symptom management Vol. 18; no. 4; pp. 271 - 279
• Main Authors: Salzman, Robert T., Roberts, Michael S., Wild, James, Fabian, Carol, Reder, Robert F., Goldenheim, Paul D.
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01-10-1999; Elsevier Science
• Subjects: Adult; Aged; Aged, 80 and over; Analgesics; Analgesics, Opioid - administration & dosage; Analgesics, Opioid - adverse effects; Analgesics, Opioid - therapeutic use; Biological and medical sciences; cancer pain; Chronic Disease; controlled-release formulation; Delayed-Action Preparations; dose conversion; Female; Humans; immediate-release formulation; low back pain; Male; Medical sciences; Middle Aged; Neuropharmacology; Oxycodone; Oxycodone - administration & dosage; Oxycodone - adverse effects; Oxycodone - therapeutic use; Pain - drug therapy; Pharmacology. Drug treatments; titration; cancer pain; titration; Oxycodone; low back pain; dose conversion; controlled-release formulation; immediate-release formulation; Human; Controlled release form; Toxicity; Treatment efficiency; Opiates; Narcotic analgesic; Analgesia; Chemotherapy; Chronic; Pain; Treatment; Immediate release form; Dosage form; Comparative study
• ISSN: 0885-3924; 1873-6513
• DOI: 10.1016/S0885-3924(99)00079-2

Two separate trials compared controlled-release (CR) oral oxycodone (administered every 12 hours) with immediate-release (IR) oxycodone (4 times a day) to determine whether patients with chronic pain could be titrated to stable pain control as readily with the CR as with the IR formulation. In one study, 48 patients with cancer pain were randomized to open-label titration with either CR or IR oxycodone (maximum dose, 400 mg/day) for a period of up to 21 days. In a study of similar design, 57 patients with low back pain were titrated with either CR or IR oxycodone (maximum dose, 80 mg/day) for a period of up to 10 days. The majority of patients in both studies were converted to oxycodone from other opioid analgesics. Results of both studies showed no difference between CR and IR oxycodone with respect to both the percentage of patients achieving stable pain control, the time to achieve stable pain control, and the degree of pain control achieved. Among cancer patients, 85% achieved stable analgesia, 92% with the CR formulation and 79% with the IR formulation. Among noncancer patients, 91% achieved stable pain control, 87% with the CR formulation and 96% with the IR formulation. The most commonly reported adverse effects in both studies were similar for the two formulations and were those anticipated with opioids: nausea, vomiting, constipation, somnolence, dizziness, and pruritus. Nausea and vomiting were the most frequently cited reasons for treatment discontinuations. These studies suggest that dose titration can be accomplished as readily with oral CR oxycodone as with IR oxycodone in patients with chronic, moderate to severe pain.